Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors - Concepedia

Concepedia

Publication | Closed Access

Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors

24

Citations

20

References

2015

Year

Didier Meulendijks, Ulrik Lassen, Lillian L. Siu, Alwin D. R. Huitema, Vaios Karanikas, Morten Mau‐Sørensen, Derek J. Jonker, Aaron R. Hansen, Mary Ellen Simcox, Kathleen Schostack,

Clinical Cancer Research

Abstract

RG7212 reduced tumor TWEAK-Fn14 signaling in a systemic exposure-dependent manner. In addition to higher exposure, relatively high Fn14 expression might be required for pharmacodynamic effect of anti-TWEAK monoclonal antibodies.

References

	Year	Citations

Page 1